Structure-activity relationship study on Tyr9 of urotensin-II(4-11): Identification of a partial agonist of the UT receptor

Peptides

Volumn 30, Issue 6, 2009, Pages 1130-1136

  Batuwangala, Madura ^a,b   Camarda, Valeria ^a   McDonald, John ^b   Marzola, Erika ^a   Lambert, David G ^b   Ng, Leong L ^b   Calo', Girolamo ^a   Regoli, Domenico ^a   Trapella, Claudio ^a   Guerrini, Remo ^a   Salvadori, Severo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Division of Clinical Pharmacology   (United Kingdom)

Author keywords

Ca2+ mobilization; Peptide synthesis; Rat aorta; Structure activity study; Urotensin II; UT receptor

Indexed keywords

NEUROPEPTIDE; TYROSINE; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II [4 11];

ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DISULFIDE BOND; DRUG ACTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; AORTA, THORACIC; CELL LINE; HUMANS; MOLECULAR CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE; UROTENSINS;

RATTUS;

EID: 67349153357     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.02.003     Document Type: Article

References (32)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Benoiton N.L. Solid-phase synthesis. Chemistry of peptide synthesis (2005), Taylor & Francis p. 125-154
3. Boivin S., Guilhaudis L., Milazzo I., Oulyadi H., Davoust D., and Fournier A. Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide. Biochemistry 45 (2006) 5993-6002
4. Boivin S., Segalas-Milazzo I., Guilhaudis L., Oulyadi H., Fournier A., and Davoust D. Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II. Peptides 29 (2008) 700-710
5. Camarda V., Guerrini R., Kostenis E., Rizzi A., Calo G., Hattenberger A., et al. A new ligand for the urotensin II receptor. Br J Pharmacol 137 (2002) 311-314
6. Camarda V., Spagnol M., Song W., Vergura R., Roth A.L., Thompson J.P., et al. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5),DTrp(7),Dab(8)]urotensin II(4-11) (UFP-803). Br J Pharmacol 147 (2006) 92-100
7. Carpino L.A., and Han G.Y. The 9-fluorenylmethoxycarbonyl amino-protecting group. J Org Chem 37 (1972) 3404-3409
8. Chatenet D., Dubessy C., Boularan C., Scalbert E., Pfeiffer B., Renard P., et al. Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist. J Med Chem 49 (2006) 7234-7238
9. Chatenet D., Dubessy C., Leprince J., Boularan C., Carlier L., Segalas-Milazzo I., et al. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25 (2004) 1819-1830
10. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
11. Darula Z., Kover K.E., Monory K., Borsodi A., Mako E., Ronai A., et al. II analogues with 6-hydroxy-2-aminotetralin-2-carboxylic acid in position 1. J Med Chem 43 (2000) 1359-1366
12. de Lecea L., and Bourgin P. Neuropeptide interactions and REM sleep: a role for urotensin II?. Peptides 29 (2008) 845-851
13. do Rego J.C., Leprince J., Scalbert E., Vaudry H., and Costentin J. Behavioral actions of urotensin-II. Peptides 29 (2008) 838-844
14. Douglas S.A., Dhanak D., and Johns D.G. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25 (2004) 76-85
15. Douglas S.A., and Ohlstein E.H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10 (2000) 229-237
16. Douglas S.A., and Ohlstein E.H. Urotensin receptors. In: Girdlestone D. (Ed). The IUPHAR compendium of receptor characterization and classification. 2nd ed. (2000), IUPHAR Media, London 365-372
17. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 82 (1959) 70-77
18. Flohr S., Kurz M., Kostenis E., Brkovich A., Fournier A., and Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45 (2002) 1799-1805
19. Grieco P., Carotenuto A., Campiglia P., Zampelli E., Patacchini R., Maggi C.A., et al. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J Med Chem 45 (2002) 4391-4394
20. Guerrini R., Camarda V., Marzola E., Arduin M., Calo G., Spagnol M., et al. Structure-activity relationship study on human urotensin II. J Pept Sci 11 (2005) 85-90
21. Heck R.F. Palladium-catalyzed vinylation of organic halides. In: Dauben W.G. (Ed). Organic reactions vol. 27 (1982), Wiley, New York 345-390
22. Kinney W.A., Almond Jr. H.R., Qi J., Smith C.E., Santulli R.J., de Garavilla L., et al. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl 41 (2002) 2940-2944
23. Labarrere P., Chatenet D., Leprince J., Marionneau C., Loirand G., Tonon M.C., et al. Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J Enzyme Inhib Med Chem 18 (2003) 77-88
24. Lavecchia A., Cosconati S., and Novellino E. Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. J Med Chem 48 (2005) 2480-2492
25. Leprince J., Chatenet D., Dubessy C., Fournier A., Pfeiffer B., Scalbert E., et al. Structure-activity relationships of urotensin II and URP. Peptides 29 (2008) 658-673
26. Lescot E., Sopkova-de Oliveira Santos J., Dubessy C., Oulyadi H., Lesnard A., Vaudry H., et al. Definition of new pharmacophores for nonpeptide antagonists of human urotensin-II. Comparison with the 3D-structure of human urotensin-II and URP. J Chem Inf Model 47 (2007) 602-612
27. McDonald J., Batuwangala M., and Lambert D.G. Role of urotensin II and its receptor in health and disease. J Anesth 21 (2007) 378-389
28. Patacchini R., Santicioli P., Giuliani S., Grieco P., Novellino E., Rovero P., et al. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 140 (2003) 1155-1158
29. Pearson D., Shively J.E., Clark B.R., Geschwind I.I., Barkley M., Nishioka R.S., et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77 (1980) 5021-5024
30. Pinder R.M., Butcher B.H., Buxton D.A., and Howells D.J. 2-Aminoindan-2-carboxylic acids. Potential tyrosine hydroxylase inhibitors. J Med Chem 14 (1971) 892-893
31. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
32. Verschueren K., Toth G., Tourwe' D., Lebl M., Van Binst G., and Hruby V. A facile synthesis of 1,2,3,4-tertahydro-7-hydroxyisoquinoline-3-carboxylic acid, a conformationally constrained tyrosine analogue. Synthesis (1992) 458-460